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1. INTRODUCTION {#mgg3667-sec-0005}
===============

Colorectal cancer is the third most common cancer worldwide and a major causes of cancer related morbidity and mortality (Bray et al., [2018](#mgg3667-bib-0003){ref-type="ref"}). In China, the incidence and mortality of colorectal cancer have a rapid increase during the past few decades (Chen et al., [2016](#mgg3667-bib-0006){ref-type="ref"}). The colorectal cancer occurrence and progression are comprehensive, multifactorial, and multistep process which caused by the interaction of environmental and genetic factors. However, the mechanism of colorectal carcinogenesis remains still not fully understood. Although obesity, sedentary behavior, and a high‐meat, high‐calorie, fat‐rich, fiber‐deficient diet, alcohol consumption, and tobacco smoking were found to be major risk factors for the development of colorectal cancer (Bishehsari, Mahdavinia, Vacca, Malekzadeh, & Mariani‐Costantini, [2014](#mgg3667-bib-0002){ref-type="ref"}; Marley & Nan, [2016](#mgg3667-bib-0017){ref-type="ref"}), only a fraction of individuals exposed to the same risk factors develop colorectal cancer during their lifetime, suggesting that other factors were associated with the development of colorectal cancer. The single nucleotide polymorphism (SNP) is the most common form of human genetic variations and are significantly associated with many cancers risk (Geng et al., [2015](#mgg3667-bib-0010){ref-type="ref"}; Hu et al., [2019](#mgg3667-bib-0011){ref-type="ref"}; Tian et al., [2018](#mgg3667-bib-0024){ref-type="ref"}). Recently, an increasing number of evidence suggests that genetic susceptibility plays an important role in the occurrence of colorectal cancer (Duan et al., [2014](#mgg3667-bib-0009){ref-type="ref"}; Su et al., [2015](#mgg3667-bib-0021){ref-type="ref"}; Wang et al., [2015](#mgg3667-bib-0026){ref-type="ref"}; Zhang, Li, Du, et al., [2014b](#mgg3667-bib-0030){ref-type="ref"}).

The miR‐17‐92a‐1 cluster host gene (MIR17HG) located on chromosome 13q31.3 in the third intron of an open reading frame termed the *c13orf25*(chromosome 13 open reading frame 25) gene. The miR‐17‐92 cluster transcript is about 800 nucleotides and encompasses six miRNAs (miR‐17, miR‐18a, miR‐19a, miR‐20a, miR‐19b‐1, and miR‐92a‐1) (Tanzer & Stadler, [2004](#mgg3667-bib-0023){ref-type="ref"}). All members of miR‐17‐92 cluster were overexpressed in colorectal cancer, pointing to a key role of miR‐17‐92 cluster in colorectal cancer carcinogenesis (Koga et al., [2010](#mgg3667-bib-0013){ref-type="ref"}). It has been reported that the *MIR17HG*overexpression is associated with poor prognosis in colorectal cancer (Yu et al., [2012](#mgg3667-bib-0028){ref-type="ref"}; Zhang, Li, Zhou, Xiao, & Zhou, [2014a](#mgg3667-bib-0029){ref-type="ref"}; Zhou, Zhang, Liu, Xia, & Tian, [2013](#mgg3667-bib-0031){ref-type="ref"}). Furthermore, functional studies have confirmed the pivotal role of members of the *MIR17HG* in the development, progression, and aggressiveness of colorectal cancer (Ma et al., [2016](#mgg3667-bib-0016){ref-type="ref"}; Tsuchida et al., [2011](#mgg3667-bib-0025){ref-type="ref"}; Zhang, Li, Zhou, et al., [2014a](#mgg3667-bib-0029){ref-type="ref"}).

However, few association studies on polymorphisms of *MIR17HG* and colorectal cancer risk has been reported (Sun et al., [2017](#mgg3667-bib-0022){ref-type="ref"}). To better understand the influence of *MIR17HG* polymorphisms on colorectal cancer susceptibility in the Chinese Han population. In this study, we recruited 514 patients with colorectal cancer and 510 healthy controls to investigate the association between polymorphisms (rs72640334, rs7336610, rs7318578, rs17735387, and rs1428) of *MIR17HG* and risk of colorectal cancer in the Chinese Han population.

2. MATERIALS AND METHODS {#mgg3667-sec-0006}
========================

2.1. Study subjects {#mgg3667-sec-0007}
-------------------

In this case--control study, we recruited of 514 colorectal cancer cases and 510 healthy control subjects from the Shaanxi Province Cancer Hospital. All cases were patients newly diagnosed with histologically confirmed colorectal cancer who were admitted to the hospital and without restrictions of age, sex, or disease stage. The patients who had received radiotherapy or chemotherapy were excluded in the study. The controls were randomly selected from the general health check‐up center at the same time period. The case and control subjects were unrelated ethnic Han Chinese and these subjects had no history of cancer. The characteristics of all subjects were taken from patients' medical records by well‐trained interviewers.

2.2. Ethics statement {#mgg3667-sec-0008}
---------------------

This study protocol was approved by the Ethics Committee of the Shaanxi Province Cancer Hospital and was conducted in accordance with the principles of the Declaration of Helsinki. All subjects provided written informed consent before the collection of blood samples.

2.3. DNA isolation {#mgg3667-sec-0009}
------------------

We used venipuncture into ethylene diamine tetraacetic acid‐coated blood vacutainer collection tubes to collect peripheral blood samples from each subject and then stored at −20°C for further DNA isolation. The GoldMag‐Mini Whole Blood Genomic DNA Purification Kit (GoldMag. Co. Ltd., Xi\'an, China) was used to extract genomic DNA from blood samples following the manufacturer\'s instructions (Liu et al., [2017](#mgg3667-bib-0015){ref-type="ref"}). The purity and concentration of the isolated DNA were analyzed using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA) by absorbance measurements at 260 and 280 nm.

2.4. SNPs selection and genotyping {#mgg3667-sec-0010}
----------------------------------

We selected the tagSNPs of *MIR17HG* with the minor allele frequency (MAF) greater than 0.05 in global population from the 1,000 Genome Projects. As a result, five tagSNPs (rs72640334, rs7336610, rs7318578, rs17735387, and rs1428) were selected using a pairwise Tagger method with *r* ^2^ \> 0.8 to capture other SNPs. Primer sequences of amplification and extension for the polymorphisms of *MIR17HG* were designed using the Agena Bioscience Assay Design Suite V2.0 software (<https://agenacx.com/online-tools/>). Genotyping was performed with the Agena MassARRAY platform with iPLEX gold chemistry (Agena Bioscience, San Diego, CA) according to the standard protocol recommended by the manufacturer. Data management and analysis were performed using the Agena Bioscience TYPER software, version 4.0.

2.5. Statistical analysis {#mgg3667-sec-0011}
-------------------------

The differences between the cases and controls in demographic characteristics were evaluated by Student\'s *t*test (for age) and Pearson\'s *χ* ^2^ test (for gender). We used the chi‐square test to assess whether the genotype frequencies of SNPs among the control group was consistent with Hardy--Weinberg equilibrium (HWE). We compared the distributions of allele frequencies of SNPs between cases and controls using the *χ* ^2^ test. The association analyses were conducted under the codominant, dominant, recessive, and additive genetic models. Logistic regression analysis was carried out to calculate odds ratios (ORs) and its 95% confidence intervals (CIs) with the adjustment of gender and age (Dai et al., [2019](#mgg3667-bib-0007){ref-type="ref"}). Pair‐wise linkage disequilibrium (LD) between the five SNPs was assessed using the Haploview software (version 4.2) (Barrett, Fry, Maller, & Daly, [2005](#mgg3667-bib-0001){ref-type="ref"}). All two‐sided *p* values less than 0.05 were considered statistically significant. The statistical analyses were performed using the Statistical Package of the PLINK software (version 1.07) (Purcell et al., [2007](#mgg3667-bib-0020){ref-type="ref"}) and Social Sciences (SPSS) software version 20.0 (SPSS Inc., Chicago, IL) and Microsoft Excel (Microsoft Corp., Redmond, WA).

3. RESULTS {#mgg3667-sec-0012}
==========

3.1. Characteristics of study subjects {#mgg3667-sec-0013}
--------------------------------------

The demographic characteristics of participants are described in Table [1](#mgg3667-tbl-0001){ref-type="table"}. Among the 1,024 participants, 514 were patients with colorectal cancer (228 females and 286 males) and 510 were healthy controls (224 females and 286 males). The mean age of the cases was 60.27 years old compared with 60.13 years old in controls, which revealed no statistically difference (*p* = 0.847). Furthermore, there was no significant difference in sex distribution *(p* = 0.839). Among the patients, the number of cases with colon cancer, rectal cancer, and other were 217 (42.2%), 244 (47.5%), and 53 (10.3%), respectively. The tumor stage for I--II, III--IV and missing were 146 (28.4%), 212 (41.2%), and 156 (30.4%), respectively.

###### 

Basic characteristics of study objects

  Characteristics   Case (%)              Control (%)     *p*             
  ----------------- --------------------- --------------- --------------- -------
  Number            514                   510                             
  Age               Mean ± *SD* (years)   60.27 ± 11.81   60.13 ± 10.61   0.847
  Gender            Female                228 (50.3)      224 (49.4)      0.839
  Male              286 (50.0)            286 (50.0)                      
  Tumor stage       I--II                 146 (28.4)                       
  III--V            212 (41.2)                                            
  Missing           156 (30.4)                                            
  LN metastasis     No                    188 (36.6)                       
  Yes               170 (33.1)                                            
  Missing           156 (30.3)                                            
  Tumor type        Colon cancer          217 (42.2)                       
  Rectal cancer     244 (47.5)                                            
  Other             53 (10.3)                                             

*p* values were calculated by Student\'s *t* test for age and *χ* ^2^test for gender.

*p* \< 0.05 indicates statistical significance.

*SD*: standard deviation; LN: lymph node
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3.2. Allele models analysis {#mgg3667-sec-0014}
---------------------------

Genotypes frequencies distributions of the five SNPs of *MIR17HG*among the healthy control were consistent with the HWE in this study, which indicated a representative distribution of the subjects in the regional population. The frequencies of rs7336610 minor allele T and rs1428 minor allele A among the patients with colorectal cancer were significantly different from those among the control subjects (*p* = 0.007; *p* = 0.008, respectively), as shown in Table [2](#mgg3667-tbl-0002){ref-type="table"}. The results revealed that individuals carrying the allele T of rs7336610 and allele A of rs1428 were associated with significantly increased risk of colorectal cancer (OR = 1.27, 95% CI: 1.07--1.51; OR = 1.27, 95% CI: 1.06--1.51, respectively). However, no statistically significant association was found between the other four *MIR17HG* polymorphisms and colorectal cancer risk in the allele model.

###### 

Association with between polymorphisms of *MIR17HG* and colorectal cancer risk

  ------------------------------------------------------------------------------------------
  SNP‐ID       Chr   Position   Alleles\   MAF     OR (95% CI)   *p*                 
                                A/B                                                  
  ------------ ----- ---------- ---------- ------- ------------- ------------------- -------
  rs72640334   13    91352674   A/C        0.084   0.096         0.86 (0.64--1.17)   0.341

  rs7336610    13    91352883   T/C        0.554   0.495         1.27 (1.07--1.51)   0.007

  rs7318578    13    91353215   C/A        0.263   0.297         0.85 (0.70--1.03)   0.089

  rs17735387   13    91353800   A/G        0.164   0.188         0.85 (0.68--1.07)   0.157

  rs1428       13    91354516   A/C        0.555   0.496         1.27 (1.06--1.51)   0.008
  ------------------------------------------------------------------------------------------

SNP: Single nucleotide polymorphism; Chr: chromosome; A: Minor alleles; B: Major alleles; MAF: Minor allele frequency; OR: Odds ratio; 95% CI: 95% Confidence interval

*p* values were calculated from *χ* ^2^ test ( two sided).

*p \< *0.05 was considered statistically significant.
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3.3. Genetic models analysis {#mgg3667-sec-0015}
----------------------------

Then, we further assessed the association between the five SNPs of *MIR17HG*and colorectal cancer risk under the four genetic models (codominant, dominant, recessive, and additive) by logistic regression analysis adjusting for gender and age (Table [3](#mgg3667-tbl-0003){ref-type="table"}). Compared to the wild homozygous genotype CC of rs7336610, individuals carrying rs7336610 TT genotype were associated with a significantly increased risk of colorectal cancer before and after adjusting for gender and age (OR = 1.57, 95% CI: 1.12--2.20, *p* = 0.009; Table [3](#mgg3667-tbl-0003){ref-type="table"}). The SNP rs7336610 was also found to be associated with an increased risk of colorectal cancer in the dominant model (TT + TC vs. CC: OR = 1.44, 95% CI: 1.08--1.92, *p* = 0.013) and the additive model (OR = 1.25, 95% CI: 1.06--1.48, *p* = 0.010) before and after adjusting for gender and age. However, we found rs7318578 was associated a decreased risk of colorectal cancer in the dominant model before adjusting for gender and age (CC + CA vs. AA: OR = 0.78, 95% CI: 0.61--1.00, *p* = 0.049).

###### 

Genetics model analysis of association between *MIR17HG* polymorphisms and colorectal cancer risk

  SNP‐ID       Model        Genotype   Case                Control             OR (95% CI)         *p*                 Adjusted OR (95% CI)   Adjusted *p*
  ------------ ------------ ---------- ------------------- ------------------- ------------------- ------------------- ---------------------- --------------
  rs72640334   Codominant   CC         426                 416                 1.00                                    1.00                    
  CA           75           90         0.81 (0.58--1.14)   0.228               0.82 (0.58--1.14)   0.234                                      
  AA           5            4          1.22 (0.33--4.58)   0.768               1.23 (0.33--4.60)   0.763                                      
  Dominant     CC           426        416                 1.00                                    1.00                                       
  AA + CA      80           94         0.83 (0.60--1.15)   0.268               0.83 (0.60--1.16)   0.275                                      
  Recessive    CC + CA      501        506                 1.00                                    1.00                                       
  AA           5            4          1.26 (0.34--4.73)   0.729               1.27 (0.34--4.75)   0.725                                      
  Additive     --           --         --                  0.86 (0.64--1.17)   0.344               0.87 (0.64--1.17)   0.352                  
  rs7336610    Codominant   CC         109                 142                 1.00                                    1.00                    
  TC           240          230        1.36 (1.00--1.85)   0.051               1.36 (1.00--1.85)   0.051                                      
  TT           165          137        1.57 (1.12--2.20)   0.009               1.57 (1.12--2.20)   0.009                                      
  Dominant     CC           109        142                 1.00                                    1.00                                       
  TT + TC      405          367        1.44 (1.08--1.92)   0.013               1.44 (1.08--1.92)   0.013                                      
  Recessive    CC + TC      349        372                 1.00                                    1.00                                       
  TT           165          137        1.28 (0.98--1.68)   0.069               1.28 (0.98--1.68)   0.070                                      
  Additive     --           --         --                  1.25 (1.06--1.48)   0.010               1.25 (1.06--1.48)   0.010                  
  rs7318578    Codominant   AA         277                 245                 1.00                                    1.00                    
  CA           199          227        0.78 (0.60--1.00)   0.052               0.78 (0.60--100)    0.054                                      
  CC           35           38         0.81 (0.50--1.33)   0.413               0.82 (0.50--1.33)   0.417                                      
  Dominant     AA           277        245                 1.00                                    1.00                                       
  CC + CA      234          265        0.78 (0.61--1.00)   0.049               0.78 (0.61--1.00)   0.051                                      
  Recessive    AA + CA      476        472                 1.00                                    1.00                                       
  CC           35           38         0.91 (0.57--1.47)   0.709               0.91 (0.57--1.47)   0.713                                      
  Additive     --           --         --                  0.84 (0.69--1.02)   0.083               0.84 (0.69--1.03)   0.087                  
  rs17735387   Codominant   GG         361                 335                 1.00                                    1.00                    
  GA           137          158        0.80 (0.61--1.06)   0.119               0.80 (0.61--1.06)   0.116                                      
  AA           16           17         0.87 (0.43--1.76)   0.704               0.87 (0.43--1.75)   0.695                                      
  Dominant     GG           361        335                 1.00                                    1.00                                       
  AA + GA      153          175        0.81 (0.62--1.06)   0.119               0.81 (0.62--1.05)   0.116                                      
  Recessive    GG + GA      498        493                 1.00                                    1.00                                       
  AA           16           17         0.93 (0.47--1.87)   0.842               0.93 (0.46--1.87)   0.837                                      
  Additive     --           --         --                  0.85 (0.68--1.07)   0.159               0.85 (0.67--1.07)   0.155                  
  rs1428       Codominant   CC         109                 142                 1.00                                    1.00                    
  CA           239          228        1.37 (1.00--1.86)   0.048               1.37 (1.00--1.86)   0.048                                      
  AA           165          138        1.56 (1.11--2.18)   0.010               1.56 (1.11--2.19)   0.010                                      
  Dominant     CC           109        142                 1.00                                    1.00                                       
  AA + CA      404          366        1.44 (1.08--1.92)   0.013               1.44 (1.08--1.92)   0.013                                      
  Recessive    CC + CA      348        370                 1.00                                    1.00                                       
  AA           165          138        1.27 (0.97--1.66)   0.081               1.27 (0.97--1.67)   0.081                                      
  Additive     --           --         --                  1.24 (1.05--1.47)   0.011               1.24 (1.05--1.47)   0.011                  

SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval

*p* \< 0.05 was considered statistically significant.
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In addition, the genotypes CA and AA of rs1428 were significantly associated with increased risk of colorectal cancer, compared to the CC genotype before and after adjusting for gender and age (CA vs. CC: OR = 1.37, 95% CI: 1.00--1.86, *p* = 0.048; AA vs. CC: OR = 1.56, 95% CI: 1.11--2.19, *p* = 0.010). In both the dominant and additive models, there were significant association between rs1428 and the risk of colorectal cancer before and after adjusting for gender and age (dominant AA + CA vs. CC: OR = 1.44, 95% CI: 1.08--1.92, *p* = 0.013; additive: OR = 1.24, 95% CI: 1.05--1.47, *p* = 0.011). However, no significant association between the other SNPs of *MIR17HG*(rs72640334 and rs17735387) and colorectal cancer risk under the four genetic models.

3.4. Tumor type stratification analysis {#mgg3667-sec-0016}
---------------------------------------

Statistical analysis based on stratification of tumor type revealed that the SNP rs7336610 was remarkably increased risk of rectal cancer after adjusting for gender and age (allele T vs. C: OR = 1.32, 95% CI: 1.06--1.64, *p* = 0.013; TC vs. CC: OR = 1.56, 95% CI: 1.05--2.33, *p* = 0.028; TT vs. CC: OR = 1.72, 95% CI: 1.12--2.66, *p* = 0.014; dominant TT + TC vs. CC: OR = 1.62, 95% CI: 1.12--2.36, *p* = 0.011; additive: OR = 1.30, 95% CI: 1.05--1.60, *p* = 0.017) (Table [4](#mgg3667-tbl-0004){ref-type="table"}). The SNP rs1428 was also found to be associated with a higher risk of rectal cancer after adjusting for gender and age (allele A vs. C: OR = 1.31, 95% CI: 1.06--1.63, *p* = 0.014; CA vs. CC: OR = 1.57, 95% CI: 1.05--2.33, *p* = 0.027; dominant AA + CA vs. CC: OR = 1.62, 95% CI: 1.12--2.36, *p* = 0.011; additive: OR = 1.29, 95% CI: 1.05--1.60, *p* = 0.018). The SNP rs7318578 had a significantly lower risk of rectal cancer (CA vs. AA: OR = 0.71, 95% CI: 0.51--0.98, *p* = 0.038; dominant CC + CA vs. AA: OR = 0.73, 95% CI: 0.54--1.00, *p* = 0.047). However, no association was found between the SNPs of *MIR17HG* and colon cancer risk.

###### 

Tumor type stratification analysis of association between *MIR17HG* polymorphisms and colorectal cancer risk

  SNP--ID      Model     Genotype   Rectal cancer       Colon cancer                                                                      
  ------------ --------- ---------- ------------------- ------------------- ------- ----- ------------------- ------------------- ------- ---
  rs7336610    Allele    C          213                 514                 1.00          199                 514                 1.00     
  T            275       504        1.32 (1.06--1.64)   0.013               235     504   1.20 (0.96--1.51)   0.106                       
  Codominant   CC        47         142                 1.00                        50    142                 1.00                        
  TC           119       230        1.56 (1.05--2.33)   0.028               99      230   1.23 (0.82--1.84)   0.310                       
  TT           78        137        1.72 (1.12--2.66)   0.014               68      137   1.42 (0.92--2.19)   0.119                       
  Dominant     CC        47         142                 1.00                        50    142                 1.00                        
  TT + TC      197       367        1.62 (1.12--2.36)   0.011               167     367   1.30 (0.90--1.89)   0.168                       
  Recessive    CC + TC   166        372                 1.00                        149   372                 1.00                        
  TT           78        137        1.28 (0.91--1.78)   0.152               68      137   1.24 (0.87--1.75)   0.229                       
  Additive     --        --         --                  1.30 (1.05--1.60)   0.017   --    --                  1.19 (0.96--1.47)   0.120   
  rs7318578    Allele    A          359                 717                 1.00          311                 717                 1.00     
  C            125       303        0.82 (0.65--1.05)   0.119               121     303   0.92 (0.72--1.18)   0.516                       
  Codominant   AA        135        245                 1.00                        111   245                 1.00                        
  CA           89        227        0.71 (0.51--0.98)   0.038               89      227   0.88 (0.63--1.22)   0.434                       
  CC           18        38         0.86 (0.47--1.56)   0.618               16      38    0.93 (0.50--1.75)   0.828                       
  Dominant     AA        135        245                 1.00                        111   245                 1.00                        
  CC + CA      107       283        0.73 (0.54--1.00)   0.047               105     265   0.88 (0.64--1.22)   0.449                       
  Recessive    AA + CA   224                            1.00                        200   472                 1.00                        
  CC           18        38         1.00 (0.56--1.79)   0.994               16      38    0.99 (0.54--1.82)   0.979                       
  Additive     --        --         --                  0.82 (0.64--1.05)   0.113   --    --                  0.92 (0.71--1.19)   0.538   
  rs1428       Allele    C          212                 512                 1.00          199                 512                 1.00     
  A            274       504        1.31 (1.06--1.63)   0.014               235     504   1.20 (0.96--1.50)   0.113                       
  Codominant   CC        47         142                 1.00                        50    142                 1.00                        
  CA           118       228        1.57 (1.05--2.33)   0.027               99      228   1.24 (0.83--1.86)   0.288                       
  AA           78        138        1.71 (1.11--2.64)   0.015               68      138   1.41 (0.91--2.17)   0.125                       
  Dominant     CC        47         142                 1.00                        50    142                 1.00                        
  AA + CA      196       366        1.62 (1.12--2.36)   0.011               167     366   1.30 (0.90--1.89)   0.162                       
  Recessive    CC + CA   165        370                 1.00                        149   370                 1.00                        
  AA           78        138        1.27 (0.91--1.77)   0.161               68      138   1.22 (0.86--1.73)   0.256                       
  Additive     --        --         --                  1.29 (1.05--1.60)   0.018   --    --                  1.18 (0.95--1.47)   0.127   

SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval

OR and 95% CI were calculated using logistic regression adjusted with age and gender.

*p* \< 0.05 was considered statistically significant.
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3.5. Gender stratification analysis {#mgg3667-sec-0017}
-----------------------------------

Gender stratification analysis found rs7336610 (allele T vs. C: OR = 1.33, 95% CI: 1.06--1.68, *p* = 0.015; dominant TT + TC vs. CC: OR = 1.48, 95% CI: 1.02--2.15, *p* = 0.039; additive: OR = 1.30, 95% CI: 1.04--1.63, *p* = 0.021) and rs1428 (allele A vs. C: OR = 1.33, 95% CI: 1.06--1.68, *p* = 0.015; AA vs. CC: OR = 1.70, 95% CI: 1.08--2.65, *p* = 0.021; dominant AA + CA vs. CC: OR = 1.50, 95% CI: 1.03--2.17, *p* = 0.034; additive: OR = 1.30, 95% CI: 1.04--1.63, *p* = 0.021) were significantly associated with increased risk of colorectal cancer after adjusting for age in males (Table [5](#mgg3667-tbl-0005){ref-type="table"}). Moreover, rs7318578 (CA vs. AA: OR = 0.66, 95% CI: 0.47--0.94, *p* = 0.020; dominant CC + CA vs. AA: OR = 0.70, 95% CI: 0.51--0.98, *p* = 0.036) and rs17735387 (GA vs. GG: OR = 0.67, 95% CI: 0.46--0.96, *p* = 0.031) were found to be associated with reduced risk of colorectal cancer after adjusting for age in males. However, no association was found between the SNPs of *MIR17HG* and colorectal cancer risk among females.

###### 

Gender stratification analysis of association between *MIR17HG* polymorphisms and colorectal cancer risk

  SNP‐ID       Model     Genotype   Male                Female                                                                            
  ------------ --------- ---------- ------------------- ------------------- ------- ----- ------------------- ------------------- ------- ---
  rs7336610    Allele    C          263                 304                 1.00          261                 236                 1.00     
  T            309       268        1.33 (1.06--1.68)   0.015               195     210   0.84 (0.65--1.09)   0.192                       
  Codominant   CC        66         88                  1.00                        76    67                  1.00                        
  TC           131       128        1.36 (0.91--2.04)   0.130               109     102   0.94 (0.61--1.44)   0.770                       
  TT           89        70         1.70 (1.08--2.65)   0.021               43      54    0.70 (0.42--1.18)   0.177                       
  Dominant     CC        66         88                  1.00                        76    67                  1.00                        
  TT + TC      220       198        1.48 (1.02--2.15)   0.039               152     156   0.86 (0.58--1.27)   0.443                       
  Recessive    CC + TC   197        216                 1.00                        185   169                 1.00                        
  TT           89        70         1.39 (0.97--2.01)   0.077               43      54    0.73 (0.46--1.14)   0.166                       
  Additive     --        --         --                  1.30 (1.04--1.63)   0.021   --    --                  0.85 (0.65--1.09)   0.199   
  rs7318578    Allele    A          413                 394                 1.00          340                 323                 1.00     
  C            155       178        0.83 (0.64--1.07)   0.155               114     125   0.87 (0.64--1.17)   0.342                       
  Codominant   AA        152        128                 1.00                        125   117                 1.00                        
  CA           109       138        0.66 (0.47--0.94)   0.020               90      89    0.95 (0.65--1.40)   0.803                       
  CC           23        20         0.97 (0.51--1.84)   0.920               12      18    0.62 (0.29--1.35)   0.231                       
  Dominant     AA        152        128                 1.00                        125   117                 1.00                        
  CC + CA      132       158        0.70 (0.51--0.98)   0.036               102     107   0.90 (0.62--1.30)   0.563                       
  Recessive    AA + CA   261        266                 1.00                        215   206                 1.00                        
  CC           23        20         1.17 (0.63--2.19)   0.618               12      18    0.64 (0.30--1.36)   0.242                       
  Additive     --        --         --                  0.82 (0.63--1.07)   0.145   --    --                  0.87 (0.64--1.17)   0.346   
  rs17735387   Allele    G          477                 457                 1.00          382                 371                 1.00     
  A            95        115        0.79 (0.59--1.07)   0.127               74      77    0.93 (0.66--1.32)   0.699                       
  Codominant   GG        203        181                 1.00                        158   154                 1.00                        
  GA           71        95         0.67 (0.46--0.96)   0.031               66      63    1.02 (0.67--1.53)   0.944                       
  AA           12        10         1.07 (0.45--2.54)   0.876               4       7     0.54 (0.15--1.88)   0.331                       
  Dominant     GG        203        181                 1.00                        158   154                 1.00                        
  AA + GA      83        105        0.70 (0.50--1.00)   0.051               70      70    0.97 (0.65--1.44)   0.872                       
  Recessive    GG + GA   274        276                 1.00                        224   217                 1.00                        
  AA           12        10         1.21 (0.51--2.86)   0.660               4       7     0.53 (0.15--1.86)   0.325                       
  Additive     --        --         --                  0.80 (0.59--1.07)   0.135   --    --                  0.92 (0.65--1.32)   0.661   
  rs1428       Allele    C          263                 302                 1.00          260                 238                 1.00     
  A            309       266        1.33 (1.06--1.68)   0.015               194     210   0.85 (0.65--1.10)   0.211                       
  Codominant   CC        66         88                  1.00                        76    68                  1.00                        
  CA           131       126        1.39 (0.93--2.07)   0.112               108     102   0.94 (0.62--1.44)   0.788                       
  AA           89        70         1.70 (1.08--2.65)   0.021               43      54    0.71 (0.42--1.19)   0.194                       
  Dominant     CC        66         88                  1.00                        76    68                  1.00                        
  AA + CA      220       196        1.50 (1.03--2.17)   0.034               151     156   0.86 (0.58--1.28)   0.464                       
  Recessive    CC + CA   197        214                 1.00                        184   170                 1.00                        
  AA           89        70         1.38 (0.96--2.00)   0.086               43      54    0.73 (0.47--1.15)   0.181                       
  Additive     --        --         --                  1.30 (1.04--1.63)   0.021   --    --                  0.85 (0.66--1.10)   0.218   

SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval

OR and 95% CI were calculated using logistic regression adjusted with age and gender.

*p* \< 0.05 was considered statistically significant.
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3.6. LD and haplotype analysis {#mgg3667-sec-0018}
------------------------------

The results of pair‐wise LD analysis with these five SNPs are shown in Figure [1](#mgg3667-fig-0001){ref-type="fig"}. We observed one haplotype block composed of rs72640334, rs7336610, rs7318578, rs17735387, and rs1428. Overall analysis found that the distributions of the frequency of the haplotype CTAGA were significantly different between colorectal cancer and control groups (*p* = 0.007); and the haplotype CTAGA was significantly associated with an increased colorectal cancer risk after adjusting for gender and age (OR = 1.26, 95% CI: 1.06--1.49) (Table [6](#mgg3667-tbl-0006){ref-type="table"}). Statistical analysis found that the haplotype CTAGA was also associated with high risk of rectal cancer after adjusting for gender and age (OR = 1.29, 95% CI: 1.04--1.59, *p* = 0.018). Furthermore, in logistic regression analysis adjusted for age and gender, the haplotype CTAGA in *MIR17HG* was associated with high risk of colorectal cancer among males (OR = 1.32, 95% CI: 1.06--1.65, *p* = 0.015).

![Haplotype block map for the five SNPs in the *MIR17HG* gene. Standard color frame is used to show LD pattern. One block in the figure showed higher LD. Bright red represents very strong LD](MGG3-7-e667-g001){#mgg3667-fig-0001}

###### 

Haplotype analysis of association between *MIR17HG*polymorphisms and colorectal cancer risk

  SNP‐ID         Haplotype   Overall   Rectal cancer   Male                                                                                                        
  -------------- ----------- --------- --------------- ------------------- ------- ------- ------- ------------------- ------- ------- ------- ------------------- -------
  rs72640334\|   CTAGA       0.558     0.496           1.26 (1.06--1.49)   0.007   0.564   0.496   1.29 (1.04--1.59)   0.018   0.544   0.469   1.32 (1.06--1.65)   0.015
  rs7336610\|    CCAAC       0.834     0.812           1.17 (0.93--1.47)   0.183   0.846   0.812   1.27 (0.95--1.70)   0.113   0.832   0.799   1.24 (0.92--1.67)   0.160
  rs7318578\|    ACCGC       0.917     0.904           1.17 (0.86--1.58)   0.323   0.918   0.904   1.18 (0.81--1.73)   0.394   0.905   0.897   1.09 (0.74--1.61)   0.657
  rs17735387\|   CCCGC       0.824     0.799           1.18 (0.94--1.49)   0.148   0.823   0.799   1.19 (0.89--1.58)   0.250   0.827   0.792   1.28 (0.94--1.75)   0.118
  rs1428         CCAGC       0.983     0.981           1.12 (0.58--2.18)   0.739   0.977   0.981   0.82 (0.38--1.74)   0.598   0.981   0.981   0.99 (0.42--2.32)   0.980

SNP: Single nucleotide polymorphism; OR: Odds ratio; 95% CI: 95% Confidence interval

OR and 95% CI were calculated using logistic regression adjusted with age and gender.

*p* \< 0.05 was considered statistically significant.
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4. DISCUSSION {#mgg3667-sec-0019}
=============

In this case--control study, we investigated the association between the polymorphisms of *MIR17HG* and colorectal cancer risk in the Chinese Han population. Overall analysis indicated that rs7336610 and rs1428 were associated with increased risk of colorectal cancer; but rs7318578 was associated with a decreased risk of colorectal cancer under the dominant model. Stratification analysis showed that rs7336610, rs7318578, rs17735387, and rs1428 were associated with colorectal cancer risk. Moreover, haplotype analysis confirmed that the haplotype CTAGA was significantly associated with an increased risk of colorectal cancer.

*MIR17HG* is located at humans chromosome 13q31, a genomic region frequently amplified in a large spectrum of human cancers including colorectal cancer. According to UALCAN database (<http://ualcan.path.uab.edu/cgi-bin/ualcan-res.pl>), we found that the expression of *MIR17HG*is significantly different between normal and colon and rectal cancer tissues (Figures [2](#mgg3667-fig-0002){ref-type="fig"} and [3](#mgg3667-fig-0003){ref-type="fig"}; Chandrashekar et al., [2017](#mgg3667-bib-0005){ref-type="ref"}). The overexpression of miR‐17‐92 cluster is not only involved in the progression of colorectal adenoma to adenocarcinoma but also related to poor survival of colorectal cancer (Diosdado et al., [2009](#mgg3667-bib-0008){ref-type="ref"}; Yu et al., [2012](#mgg3667-bib-0028){ref-type="ref"}). Previous study demonstrated that miR‐17‐92 suppressed colorectal cancer progression by inhibiting tumor angiogenesis in a genetically engineered mouse model, indicating the presence of cellular context‐dependent pro‐ and anti‐cancer effects of miR‐17‐92 (Ma et al., [2016](#mgg3667-bib-0016){ref-type="ref"}). It also found that higher levels of miR‐17‐92 contribute to inhibition of tumor growth and metastasis in a mouse tumor model (Jiang et al., [2014](#mgg3667-bib-0012){ref-type="ref"}). Recent research identified that the miR‐17‐92 cluster was a crucial player in the development of the immune system (Kuo, Wu, & Yang, [2018](#mgg3667-bib-0014){ref-type="ref"}). Previous study indicated that *MIR17HG* copy numbers would seem to be related to response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (Molinari et al., [2016](#mgg3667-bib-0018){ref-type="ref"}). Moreover, it has been reported that the miR‐92 upregulation in plasma may be used as a noninvasive molecular marker for colorectal cancer screening, with a sensitivity of 89% and a specificity of 70% (Ng et al., [2009](#mgg3667-bib-0019){ref-type="ref"}). These findings suggest that miR‐17‐92 cluster play a pivotal role in the of development colorectal cancer.

![The expression of *MIR17HG* between normal and colon adenocarcinoma tissues from the UALCAN database. COAD: colon adenocarcinoma](MGG3-7-e667-g002){#mgg3667-fig-0002}

![The expression of *MIR17HG* between normal and rectum adenocarcinoma tissues from the UALCAN database. READ: Rectum adenocarcinoma](MGG3-7-e667-g003){#mgg3667-fig-0003}

Previous study reported that two functional polymorphisms (rs9588884 and rs982873) in the promoter region of miR‐17‐92 cluster are associated with a decreased risk of colorectal cancer (Sun et al., [2017](#mgg3667-bib-0022){ref-type="ref"}). It has been reported that the SNP rs9515692 in the promoter region of miR‐17‐92 was a protective factor for the susceptibility of systemic lupus erythematosus (Wang et al., [2018](#mgg3667-bib-0027){ref-type="ref"}). Statistical analysis of allele frequencies in cases and controls in the Genomics Research Centre Breast Cancer population for rs7336610 showed significance; and haplotypic analysis of results showed that the AC haplotype of rs4824505/rs7336610 are associated with risk of breast cancer development (Chacon‐Cortes, Smith, Lea, Youl, & Griffiths, [2015](#mgg3667-bib-0004){ref-type="ref"}). In this study, we investigated the association between the polymorphisms of *MIR17HG* and colorectal cancer risk in the Chinese Han population. The results indicated that the two SNPs (rs7336610 and rs1428) of *MIR17HG*were associated with increased colorectal cancer risk, but the two SNPs (rs7318578, rs17735387) of *MIR17HG* were associated with decreased colorectal cancer risk in the Chinese Han population. To date, no association study was carried out to investigate the association of SNPs (rs72640334, rs7336610, rs7318578, rs17735387, and rs1428) of *MIR17HG* and colorectal cancer risk. Therefore, further association study with a large sample is needed to confirm these results.

There are some potential limitations in this study must be considered. First, only subjects of Chinese Han descent were included in this study, additional studies included different ethnic populations should be conducted to confirm these results. Second, data were not available for some risk factors (e.g., cigarette smoking, alcohol consumption), which prevented our further gene‐environment interaction analysis. Third, functional studies were not performed in this study. More detailed data are required to create a comprehensive understanding of the *MIR17HG* in colorectal cancer tumorigenesis.

5. CONCLUSIONS {#mgg3667-sec-0020}
==============

In conclusion, this study provides the first evidence that the polymorphisms (rs7336610, rs7318578, rs17735387, and rs1428) of *MIR17HG* were associated with colorectal cancer risk. Therefore, our findings may provide new insights into the development of colorectal cancer. Further association and functional studies are of great importance to confirm these results and help us to define the potential biological mechanism of colorectal cancer.
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